Organisation paid for research Program year 2025 Source: CMS Open Payments

Mercy Clinics, Inc.

Neither a doctor nor a teaching hospital

Research payments

$146,369

31 payments

Through program year 2025, Mercy Clinics, Inc. is reported as receiving $146,369 in research payments, across 31 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$2,650	4
2024	Research	$29,106	2
2023	Research	$10,780	1
2019	Research	$103,833	24

Breakdown

Who paid Research payments · program years 2019–2025

Sanofi US Services Inc. $103,833 24 payments
EMD Serono, Inc. $42,536 7 payments

Studies the money was for Research payments · program years 2019–2025

Randomized, Open Label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity of Alternating Use of SAR341402 and NovoLog Versus Continuous Use of NovoLog in Participants With Type 1 Diabetes Mellitus Also Using Insulin Glargine $34,400 2 payments
Six-month, Randomized, Open-label, Parallel-group Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Also Using Insulin Glargine, With a 6-month Safety Extension Period $30,004 7 payments
AGING Study $29,106 2 payments
Randomized, Open Label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity of Alternating Use of SAR341402 and NovoLog Versus Continuous Use of NovoLog in Participants With Type 1 $15,723 1 payment
A Multicenter, Observational Study to Characterize the Clinical Course in a Real-World, US Cohort of Patients with Relapsing Multiple Sclerosis of Advanced Age (? 50 years) Treated with Cladribine Tablets (AGING Study) $10,780 1 payment
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function $9,366 7 payments
Safety Assessment of SAR341402 and NovoLog Used in Continuous Subcutaneous Insulin Infusion (CSII) in Adult Patients With Type 1 Diabetes Mellitus (T1DM) $7,984 4 payments
Evaluation of Virtual Versus Traditional Study Conduct in a 6-month, Multicenter, Randomized, Open-label, Two-parallel Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus $5,669 2 payments
A Multicenter, Observational Study to Characterize the Clinical Course in a Real-World, US Cohort of Patients with Relapsing Multiple Sclerosis of Advanced Age (>50 years) Treated with Cladribine Tablets (AGING Study) $2,650 4 payments
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardi $687 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.